Illegal medicinal drug ring busted in Punjab, Delhi and UP, 7 lakh tablets seized
The NCB has unearthed an inter-state nexus of psychotropic ...
Lupin gets 5 observations from USFDA for its Vizag facility
The inspection of company's Vizag API manufacturing facility by the United States...
Strides gets USFDA nod for anti-allergic drug
The company said, it is focusing on building a private label business in the US by leveraging i...
IIT Roorkee researchers find antibiotic against multi-drug resistant bacteria
In a new study published in the journal, ‘Journal of Antimicrobial Chemotherapy’, IIT Roorkee researchers screened a library of 11,000 compounds against the Gram negative bacteria, Escherichia coli and discovered 30 novel potent antibacterials.
Wockhardt rallies after revival plan gets a boost from drug nod
Investors cheered the news, sending Wockhardt’s shares up by 5.7 per cent on the BSE on Thursday.
Pharma cos may face Rs 10-lakh penalty, 2-year jail term for deceptive drug ads
Pharmaceutical companies or anybody involved in exaggerating how well their drugs work will face exemplary penalty and imprisonment, according to the proposed amendments to the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
USFDA classifies inspection of Lupin's Tarapur facility as 'Official Action Indicated'
According to FDA's definitions, Official Action Indicated means "objectionable conditions were found and regulatory administrative sanctions by FDA are indicated" during inspections. The company, however, said that it does not believe this inspection classification will have an impact on disruption of supplies or the existing revenues from operations of this facility.
After price cap, local stent makers capture 60% of market
Price regulation has also allowed better margins to Indian companies even as locally made, lower-priced products gain in the market, helping local players increase revenues. The share of Indian companies in terms of value has increased from 30% in 2016-17 to over 55% in 2019-20.
HC Bars Cipla, 3 others from launching generic version of Bristol-Myers’ drug
Delhi High Court has granted an injunction restraining the domestic pharma companies such as Cipla, Torrent, Emcure, Alkem from selling a medicine used for prevention and treatment of thromboembolic diseases, the patent for which is held by Bristol-Myers Squibb (BMS) as it filed its claims for patent infringement of Apixaban in Delhi HC.
Experts to decide on inclusion and exclusion of antibiotics from NLEM today
Government-appointed experts have been tasked with preparing the new NLEM to decide on which group of antibiotics should be included and excluded from the list, in a bid to curb indiscriminate use of antibiotics. The revision of NLEM ensures that antibiotics are available when needed and right antibiotics are prescribed for the right infections.
Top cancer drugs may come under price control
Taking cue from the WHO’s revised list of essential medicines, popular biosimilars for cancer cure may get incorporated in India’s revised National List of Essential Medicines.
Government mulls tax break for Indian pharma companies
The government had introduced a weighted tax deduction of 200% on expenditure on R&D in the 2010 budget, in order to boost innovation in the country. However, the government slashed the benefit to 150% from 2017 onwards and 100% from 2020.
True North buys into Biocon Biologics, deal values firm at around $3.5 billion
True North has acquired about 3 per cent of Biocon Biologics India Ltd (BBIL), a wholly owned subsidiary of Biocon, for $100 million, valuing the unlisted arm at $3-3.5 billion (Rs 25,000 crore), said two people aware of the development. This is the first step of a larger $200-300 million fundraising round that’s expected to close before mid-2020.
Exaggerated drug ads to bring fines, stringent charges
Ministry sets up panel to suggest stronger criminal procedures against violators. At present, penalties for false claims include “imprisonment which may extend to six months, fine, or both” in the case of the first conviction. In the case of a subsequent conviction, imprisonment “may extend to one year, or fine, or both”.
Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service